Reimbursement of metformin for polycystic ovary syndrome

Endokrynologia Polska

Volumn 64, Issue 5, 2013, Pages 409-414

  Milewicz, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Metabolic abnormalities; Metformin; PCOS

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; BODY MASS; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOGENESIS; PHENOTYPE; REIMBURSEMENT; ALGORITHM; COMPLICATION; FEMALE; OFF LABEL DRUG USE; POLYCYSTIC OVARY SYNDROME;

ALGORITHMS; FEMALE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; METFORMIN; OFF-LABEL USE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME;

EID: 84888862076     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2013.0025     Document Type: Article

References (63)

1. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM - Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97: 28-38.e25.
2. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR. Polycystic ovary syndrome. Boston: Blackwell Scientific 1992; 377-384.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
4. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005; 83: 1343-1346.
5. Legro R. American Endocrine Society, Curr Opin Endocrinol Diabetes Obes 2008; 15: 30-36.
6. Takara S. Current Opinion in Endocrinol Diabetes and Obesity 2008; 15: 30-36.
7. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The moleculargenetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26: 251-282.
8. Dunaif A, Xia J, Book CB, Schenker E et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-810.
9. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28: 341-359.
10. Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocr Rev 1997; 18: 774-800.
11. Lerchbaum E, Obermayer-Pietsch B. Vitamin D and fertility - a systematic review. Eur J Endocrinol 2012, 166, 765-778.
12. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110-3116.
13. Poretsky L, Cataldo NA, Rosenwaks Z et al. The insulin - related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582.
14. Zhang G, Garmey JC, Veldhuis JD. Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells. Endocrinology 2000; 141: 2735-2742.
15. Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca - interstitial cells. Fertil Steril 1998; 69: 335-340.
16. McGee E, Sawetawan C, Bird I et al. The effects of insulin on 3 beta hydroksysteroid dehydrogenase expression in human luteinized granulose cells. J Soc Gynecol Investing 1995; 2: 535-541.
17. Miller WL. Molecular biology of steroid hormone synthesis. Enocrinol Rev 1988; 9: 295-318.
18. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617-623.
19. Nestler JE, Matt DW, Steingold K et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89.
20. Moghetti P, Castello R, Negri C et al. Insulin infusion amplifies 17-a hydroxycorticosteroid intermediates response to ACTH in hyperandrogenic women: apparent relative impairment of 17, 20-lyase activity. J Clin Endocrinol Metab 1996; 81: 881-886.
21. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 863-861.
22. Yildiz BO, Bozdag G, Yapici Z et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27: 3067-3073.
23. Moran C, Tena G, Moran S et al. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest 2010; 69: 274-280.
24. Moran LJ, Hutchison SK, Norman RJ et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011: CD007506.
25. Glueck CJ, Wang P, Kobayashi S et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520-525.
26. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F et al. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 2007; 22: 3197-3203.
27. Talbott EO, Zborowski JV, Rager JR et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5454-5461.
28. Carmina E, Orio F, Palomba S et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006; 119: 356e1-6.
29. Foltyn W, Strzelczyk J, Marek B et al. Selected markers of endothelial dysfunction in women with polycystic ovary syndrome. Endokrynol Pol 2011; 62: 243-248.
30. Kelly CCJ, Lyall H, Petrie JR et al. Low Grade Chronic Inflammation in Women with Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 2001; 86: 2453-2455.
31. Guzelmeric K, Alkan N, Pirimoglu M et al. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 2007; 23: 505-510.
32. Fenkci IV, Serteser M, Fenkci S et al. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007; 52: 879-883.
33. Atiomo WU, Fox R, Condon JE et al. Raised plasminogen activator inhibitor- 1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000; 52: 487-492.
34. Glueck CJ, Wang P, Fontaine RN et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999; 48: 1589-1595.
35. Benson S, Janssen OE, Hahn S et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun 2008; 22: 177-184.
36. Sayin NC, Gucer F, Balkanli-Kaplan P et al. Elevated serum TNF-alpha in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003; 48: 165-170.
37. Gonzalez F, Rote NS, Minium J et al. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1508-1512.
38. Mahmood K, Naeem M, Rahimnajjad NA. Metrofmin: The hidden chronicles of a magic drug. European Journal of Internal Medicine 2013; 24: 20-26.
39. Gregorio F, Ambrosi F, Manfrini S et al. Metformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study. Diabet Res Clin Pract 1997; 37: 21-33.
40. Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; CD002966.
41. Lord JM, Flight LH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ 2003; 327: 951-953.
42. Kurukulasuriya R, Banerji MA, Chaiken R et al. Selective decrease in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes. Diabetes 1999; 48 (Suppl.): A315.
43. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med 1995; 333: 541-549.
44. KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350.
45. De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Int Med 2005; 257: 100-109.
46. Haffner S, Temprosa M, Crandal J et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572.
47. Mamputu JC, Wiernsperger N, Renier G. Metformin inhibits monocyte adhesion to endothelial cells and foam cell formation. Br J Diabet Vasc Dis 2003; 3: 302-310.
48. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Dabet Metab 2003; 29: 6595-65103.
49. Schwimmer JB, Middleton MS, Deutsch R et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2005; 21: 871-879.
50. Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
51. Orio F Jr, Palomba S, Cascella T et al. Improvement in endothelial structure andfunction after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005; 90: 6072-6076.
52. Diamanti-Kandarakis E, Alexandraki K, Protogerou A et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152: 749-756.
53. Morin-Papunen L, Rautio K, Ruokonen A et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649-4654.
54. Topcu S, Tok D, Caliscan M et al. Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clin Endocrinol 2006; 65: 75-80.
55. Harborne LR, Sattar N, Norman JE et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005; 90: 4593-4598.
56. Lord JM, Flight LH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2003; 3: CD003053.
57. Costello MF. Shrestha B, Eden J et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod 2007; 22: 1200-1209.
58. Harborne L, Fleming R, Lyall H et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4116-23.
59. Cosma M, Swiglo BA, Flynn DN et al. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93: 1135-1142.
60. Glueck CJ, Wang P, Fontaine R et al. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48: 511-519.
61. Consensus on infertility treatment related to polycystic ovary syndrome. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, March 2-3, 2007. Fertil Steril 2008; 89: 505-522.
62. Nestler JE, Azziz R. Dyskusja ekspertów American Endocrine Society, San Francisco, 2008.
63. Khattab S, Mohsen LA, Foutouh LA et al. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22: 680-684.